On March 17, 2026 Adagene Inc. ("Adagene or the Company") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, reported that muzastotug will be highlighted in two poster presentations at this year’s AACR (Free AACR Whitepaper) Meeting, taking place April 17-22 in San Diego, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The following abstracts have been selected for presentation at AACR (Free AACR Whitepaper) 2026:
Title: Ph1b evaluation of ADG126 (muzastotug, an anti-CTLA-4 masking antibody) pembrolizumab (Pembro) IO doublet in combination with fruquintinib (Fruq) in advanced and metastatic microsatellite stable colorectal cancer
Session Title: Phase I Clinical Trials in Progress
Session Start: April 20, 2026, 9:00 AM – 12:00 PM Pacific Time
Location: Poster Section 51
Poster Board Number: 14
Abstract Presentation Number: CT083
Title: Results from the phase 1b/2 Morpheus Liver study in patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC): Muzastotug (ADG126: masked anti-CTLA-4 Ab) combination arm
Session Title: First-in-Human Phase I Clinical Trials
Session Start: April 20, 2026, 9:00 AM – 12:00 PM Pacific Time
Location: Poster Section 50
Poster Board Number: 14
Abstract Presentation Number: CT054
(Press release, Adagene, MAR 17, 2026, View Source [SID1234663665])